Sinbaglustat

Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2) . Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions[1][2].

Product Specifications

CAS Number

[441061-33-2]

Product Name Alternative

ACT-519276; OGT2378

UNSPSC

12352005

Target

Glucosylceramide Synthase (GCS)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/sinbaglustat.html

Purity

99.83

Solubility

DMSO : 83.33 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@H](CO)N(CCCCC)C[C@H](O)[C@H]1O

Molecular Formula

C11H23NO4

Molecular Weight

233.30

References & Citations

[1]Michael Weiss, et al. Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res. 2003 Jul 1;63 (13) :3654-8. |[2]Martine Gehin, et al. Assessment of Target Engagement in a First-in-Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders. Clin Transl Sci. 2021 Mar;14 (2) :558-567.